Page 27 - Flipbook

COMMENTARY

Lenvatinib Pembrolizumab overall QOL is about the same

with some exceptions

• Cannot do cross trial comparisons

• Cabo/Nivo and Ipi/Nivo both have QOL improvement over SU

Axitinib Pembrolizumab continues to be efficacious

• Favorable risk HR 1.17 but not stat sig and not powered to

detect this difference; note CR rate of 11.6 vs 6.1

• There doesn’t appear to be a tail of the curve

The big debate continues to be:

• VEGFIO Good Response vs Ipi/Nivo Tail of the Curve